相关实验视频
Updated: Sep 14, 2025
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.0K
SGLT2 抑制剂:从血糖控制到心脏脏保护
Kh Evloev1, D Snitsa2, D Pankov2
11North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia.
Georgian medical news
|July 22, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂提供了除了糖尿病管理之外的显著心脏和脏保护. 临床试验揭示了血液动力学调节和抗炎作用等机制,确定SGLT2抑制剂是心脏和脏健康的关键.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂最初是针对2型糖尿病 (T2DM) 的.
- 新出现的证据突出显示,它们的实质性心脏保护和脏保护益处独立于血糖控制.
- 这些影响需要对其机制和临床应用进行全面的审查.
研究的目的:
- 审查SGLT2抑制剂的心脏保护和保护作用背后的机制.
- 总结不同患者群体的临床影响,包括患有和没有糖尿病的患者.
- 评估SGLT2抑制剂在心力衰竭和慢性病中的作用.
主要方法:
- 对具有里程碑意义的心血管和结局试验的综述.
- 评估生理和分子机制 (血液动力学调制,抗炎/抗纤维素作用,能量学).
- 评估SGLT2抑制剂在心力衰竭 (HFrEF/HFpEF) 和慢性病 (CKD) 中的疗效.
主要成果:
- SGLT2 抑制剂在心血管和结局方面显示出显著的益处.
- 机制包括改善心肌和功能,减少炎症和抗纤维作用.
- 在心力衰竭和CKD中,无论糖尿病状况如何,都显示出有效性.
结论:
- 除了降低葡萄糖,SGLT2抑制剂还提供了相当大的心脏和脏保护.
- 它们的多方面的机制支持它们在治疗心力衰竭和CKD中的使用.
- 临床指导方针现在承认SGLT2抑制剂对心脏和脏保护至关重要.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
305
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
305
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:23Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
265
01:24Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
01:17Oral Hypoglycemic Agents: Sulfonylureas
342
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
342